Word

HELA 3.0

Status

Dead

Status Code

602

Status Date

Thursday, October 13, 2022

Serial Number

90718951

Mark Type

4000

Filing Date

Tuesday, May 18, 2021

Abandoned Date

Monday, October 3, 2022

Trademark Owner History

Ultragenyx Pharmaceutical Inc.

Classifications

1 Chemical, biological, and biochemical products for use in gene delivery technology, namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, for in vitro laboratory use and in vivo therapeutic use in gene therapy; chemical, biological, and biochemical products for use in the manufacture of pharmaceutical preparations

45 Licensing of intellectual property

44 Providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of genetic diseases and disorders; providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of liver, hepatological, cardiovascular, central nervous system, endocrine, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, respiratory, and hematologic diseases and disorders; medical information services in the nature of providing a database in the field of gene therapy information based on collected patient data and information all for treatment and diagnostic purposes; medical information services

42 Research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery development of biochemical assays; compiling and sharing of patient data for research purposes in the field of medical science

HELA THREE POINT ZERO; HEAL THREE ZERO

Trademark Events

Oct 13, 2022

Abandonment Notice E-Mailed - Failure To Respond

Oct 13, 2022

Abandonment Notice Mailed - Failure To Respond

Oct 13, 2022

Abandonment - Failure To Respond Or Late Response

Mar 31, 2022

Notification Of Non-Final Action E-Mailed

Mar 31, 2022

Non-Final Action E-Mailed

Mar 31, 2022

Non-Final Action Written

Jan 27, 2022

Assigned To Examiner

Aug 16, 2021

New Application Office Supplied Data Entered In Tram

May 21, 2021

New Application Entered In Tram